Van den Bossche J, De Laere M, Deschepper K, Germonpre P, et al. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study. PLoS One 2024;19:e0307204.
PMID: 39008481